The NEET SS 2024 Diploma in Tuberculosis and Chest Disease Question Paper 2 was conducted as part of the national-level super speciality examination for admissions into DM and MCh programmes. This paper evaluates a candidate’s advanced understanding of pulmonary medicine, tuberculosis management, respiratory infections, critical care, imaging interpretation, interventional pulmonology, and evidence-based clinical decision-making. Candidates were required to attempt 100 questions in 150 minutes, with a total of 400 marks. Each correct answer awards 4 marks, while 1 mark is deducted for every incorrect response as per the NEET SS negative marking scheme.

NEET SS 2024 Diploma Tuberculosis and Chest Disease Question Paper 2 with Answer Key PDF

NEET SS 2024 Diploma Tuberculosis and Chest Disease Question Paper with Solutions PDF Download PDF Check Solutions
NEET SS Diploma Tuberculosis and Chest Disease Paper 2 Preview

NEET SS 2024 Diploma Tuberculosis and Chest Disease Question Paper 2 with Solutions


Question 1:

a) Pulmonary Langerhans cell histiocytosis (PLCH). [5]


Question 1:

b) Lymphangioleiomyomatosis (LAM). [5]


Question 2:

a) Diagnosis and treatment of pneumocystis pneumonia. [5]


Question 2:

b) Treatment of pulmonary non-tuberculous mycobacterial (NTM) disease. [5]


Question 3:

a) Management of empyema. [5]


Question 3:

b) Management of tuberculosis in patient with renal disease. [5]


Question 4:

a) Diagnosis of the bronchiectasis. [5]


Question 4:

b) Management for inoperable patients of mycetoma lung. [5]


Question 5:

a) Radiological features of lung hydatid disease. [5]


Question 5:

b) Management for severe exacerbations of COPD. [5]


Question 6:

a) Tropical pulmonary eosinophilia. [5]


Question 6:

b) Treatment of pulmonary cystic echinococcosis. [5]


Question 7:

a) Molecular targeted therapy in advanced non-small-cell lung cancer. [5]


Question 7:

b) Treatment of sarcoidosis in patients who progress on or cannot use methotrexate. [5]


Question 8:

a) Sleep disorders related to abnormalities in REM sleep. [5]


Question 8:

b) Positive airway pressure (PAP) therapy for adults with obstructive sleep apnea (OSA). [5]


Question 9:

a) Surgical emphysema. [5]


Question 9:

b) Lung carcinoid tumors. [5]


Question 10:

a) Nicotine replacement therapies. [5]


Question 10:

b) Treatment of sarcoidosis in patients who progress on or cannot use methotrexate. [5]